Prostate Specific Antigen ELISA Kit

Produktnummer ABIN996897

Dieses Human Prostate Specific Antigen ELISA-Kit ist ein Colorimetric ELISA-Kit, das dafür entwickelt wurde, Human Prostate Specific Antigen zu quantifizieren.

Kurzübersicht für Prostate Specific Antigen ELISA Kit (ABIN996897)

Target: Prostate Specific Antigen (PSA)

Reaktivität: Human

Nachweismethode: Colorimetric

Methodentyp: Sandwich ELISA

Detektionsbereich: 0-60 ng/mL

Applikation: ELISA

Proben: Serum

Produktdetails Prostate Specific Antigen ELISA Kit

Untere Nachweisgrenze: 0 ng/mL

Verwendungszweck: The PSA Enzyme Immunoassay test kit is intended for the quantitative determination of PSA in human serum.

Analytische Methode: Quantitative

Spezifität: 98.7 %

Sensitivität: 0.5 ng/mL

Anwendungsinformationen

Probenmenge: 25 μL

Testdauer: 1 h

Plattentyp: Pre-coated

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Lagerung: 4 °C

Haltbarkeit: 12 months

Details zu Prostate Specific Antigen

Target: Prostate Specific Antigen (PSA)

Andere Bezeichnung: PSA

Hintergrund: Human prostate-specific antigen (PSA) is a serine protease, a sigle chain glycoprotein with a molecular weight of approximately 34,000 daltons containing 7% carbohydrate by weight. PSA is immunologically specific for prostatic tissue, it is present in normal, benign hyperplastic, and malllignant prostatic tissue, in metastatic prostatic carcinoma, and also in prostatic fluid and seminal plasma. PSA is not present in any other normal tissue obtained from men, nor is it produced by cancers of the breast, lung, colon, rectum, stomach, pancreas or thyroid. Besides, it is functionally and immunologically different from prostatic acid phosphatase (PAP). Elevated serum PSA concentrations have been reported in patients with prostate cancer, benign prostatic hypertrophy, or inflammatory conditions of other adjacent genitourinary tissues, but not in apparently healthy men, men with non-prostatic carcinoma, apparently healthy women, or women with cancer. Reports have suggested that serum PSA is one of the most useful tumor markers in oncology. It may serves as an accurate marker for assessing response to treatment in patients with prostatic cancer. Therefore, measurement of serum PSA concentrations can be an important tool in monitoring patients with prostatic cancer and in determining the potential and actual effectiveness of surgery or other therapies. Recent studies also indicate that PSA measurements can enhancce early prostate cancer detection when combined with digital rectal examination (DRE).

Pathways: Komplementsystem